Trial Profile

A Phase Ib Trial of BYL719 (an alpha-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Letrozole
Indications Advanced breast cancer; Carcinoma
Focus Adverse reactions
Sponsors Novartis

Most Recent Events

19 Aug 2026 Status changed from active, no longer recruiting to completed.
23 Jul 2024 Planned End Date changed from 31 May 2024 to 28 Feb 2025.
04 Dec 2023 Planned End Date changed from 1 Oct 2023 to 31 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com